Inserm Transfert and Innate Pharma sign antibody deal
This article was originally published in Scrip
Executive Summary
Innate Pharma is to evaluate Inserm Transfert's early-stage antibody targets to develop potential treatments for cancer, inflammation and auto-immune diseases.